IDEXX Laboratories, Inc. (NASDAQ:IDXX) is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 1.43 per share.
Looking ahead, the full year income are expected at $ 5.64 per share on the revenues of $ 2608.04 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2,620.00 million ~ $ 2,655.00 million, where as bottomline are predicted in a range of $ 5.42 ~ $ 5.58 per share
Click Here For More Historical Outlooks Of IDEXX Laboratories, Inc.
Previous Quarter Performance
IDEXX Laboratories, Inc. unwinded income for the second quarter of $ 1.72 per share, from the revenue of $ 637.59 million. The quarterly earnings improved 20.28 percent while revenues escalated 2.82 percent compared with the same quarter last year.
Wall street analysts are predicting, IDXX to report 2Q20 income of $ 1.16 per share from revenue of $ 589.98 million. The bottom line results beat street analysts by $ 0.56 or 48.28 percent, at the same time, top line results outshined analysts by $ 47.61 million or 8.07 percent.
Stock Performance
Shares of IDEXX Laboratories, Inc. traded low $ -20.27 or -4.57 percent on Wednesday, reaching $ 422.89 with volume of 464.80 thousand shares. IDEXX Laboratories, Inc. has traded high as $ 441.48 and has cracked $ 422.11 on the downward trend
According to the previous trading day, closing price of $ 422.89, representing a 162.77 % increase from the 52 week low of $ 168.65 and a 0.4 % decrease over the 52 week high of $ 444.96.
The company has a market capital of $ 35.97 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
IDEXX Laboratories, Inc. will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.idexx.com
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
